-
Dec 4, 2024 | 
nature.com | Ildiko Lingvay
AbstractTreatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) may attenuate kidney disease progression and cardiovascular events but their real-world impact on healthcare utilization and mortality in this population are not well-defined.
-
Aug 16, 2024 | 01210-8/abstract&sz=64)
thelancet.com | Ildiko Lingvay |Ricardo V. Cohen |College Dublin
Get full text accessLog in, subscribe or purchase for full access. References2. NCD Risk Factor CollaborationEvolution of BMI over time3. Collaboration NCDRFTrends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participantsLancet. 2016; 387:1377-13964. Anekwe, CV ∙ Jarrell, AR ∙ Townsend, MJ ∙ et al. Socioeconomics of obesityCurr Obes Rep. 2020; 9:272-2795.
-
Jul 1, 2024 | 
digitalcommons.library.tmc.edu | Donna Ryan |Ildiko Lingvay |John Deanfield |Steven Kahn
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.
-
May 24, 2024 | 
healio.com | Jill Rollet |Ildiko Lingvay
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: An FDA committee voted against recommending insulin icodec to improve glycemic control in type 1 diabetes. Concerns over hypoglycemia risk and lack of data on risk mitigation were discussed.
-
May 13, 2024 | 
nature.com | Ildiko Lingvay |Eric Barros |Helen M. Colhoun |Cintia Cercato |A. Michael Lincoff |Jorge Plutzky
AbstractIn the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).
-
Apr 1, 2024 | 
jacc.org | Reza Mohebi |Philip Jones |John A. Spertus |Ildiko Lingvay
References1. "The importance of worsening heart failure: hiding in plain sight". J Am Coll Cardiol . 2022;80:123-125. https://doi.org/10.1016/j.jacc.2022.04.044. 2. "Treatment for heart failure: endpoints for drug development guidance for industry". Accessed February 5. 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry. 3.
-
Jan 1, 2024 | 
jacc.org | Josephine Harrington |G. Michael Felker |Ildiko Lingvay |Neha J. Pagidipati
References1. "Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study". Circulation . 2023;147:1872-1886. 2. "Obesity and cardiovascular disease: a scientific statement from the American Heart Association". Circulation . 2021;143:e984-e1010. 3. "Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction". Circulation . 2017;136:6-19. 4.
-
Sep 21, 2023 | 
nature.com | Ildiko Lingvay
Mounting evidence, including the recent (and unprecedented) phase 2 data on retatrutide, supports a role for incretin hormone agonists in treating obesity. But with great power comes great responsibility. The worldwide obesity epidemic is continuing unabated and is projected to worsen over the next decades.
-
Jul 25, 2023 | 00191-2/abstract&sz=64)
thelancet.com | Ildiko Lingvay |Priya Sumithran |College Dublin |Ricardo V. Cohen
Treating obesity has wide-ranging benefits on health and wellbeing. 1Lingvay I Sumithran P Cohen RV le Roux CW Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Advances in medications for obesity have sparked interest, and excessive unregulated media attention has driven unprecedented demand for these new agents. However, the media coverage risks propagating the view that there is a magic bullet treatment for obesity.
-
Feb 16, 2023 | 
dispatchist.com | Ildiko Lingvay
February 16, 2023 by Credit: Pixabay/CC0 Public Domain Two classes of drugs prescribed off-label for some patients with type 1 diabetes can provide significant benefits, but also come with health concerns, according to a study by UT Southwestern Medical Center researchers.The findings, published in The Journal of Clinical Endocrinology & Metabolism, provide a rare view of real-world use of these medications, which are growing in popularity among patients with type 1 diabetes as adjuvants to...
